In Vitro and in Vivo Studies of FePt Nanoparticles for Dual Modal CT/MRI Molecular Imaging
In Vitro and in Vivo Studies of FePt Nanoparticles for Dual Modal CT/MRI Molecular Imaging
复制标题
DOI：
10.1021/ja1035013
复制
发表时间：
2010-09-29
影响因子：
15
通讯作者：
Chen, Chia-Chun
中科院分区：
文献类型：
--
作者：
Chou, Shang-Wei;Shau, Yu-Hong;Chen, Chia-Chun
合成了直径为3、6和12 nm的水溶性FePt纳米颗粒（3 nm-、6 nm-和12 nm-FePt），并将其用作CT/MRI分子成像的双模态造影剂。这些纳米颗粒在所有测试浓度下都具有优异的生物相容性和血液相容性，用于成像对比。生物分布分析显示12 nm-FePt的血清浓度和循环半衰期最高，其次是6 nm-FePt，然后是3 nm-FePt。因此，3 nm-FePt显示出更高的脑浓度。抗Her 2抗体缀合的FePt纳米颗粒在MBT 2细胞系及其Her 2/neu基因敲除对应物中表现出分子表达依赖性CT/MRI双重成像对比效应。在尾静脉注射纳米颗粒后，在携带肿瘤的动物中发现CT和MRI中Her 2/neu过表达癌症病变的选择性对比增强。在两种成像模式中，12 nm-FePt优于3 nm-FePt。这些结果表明FePt纳米颗粒在临床环境中作为新型多模态分子成像造影剂的潜力。
The water-solvable FePt nanoparticles of 3, 6, and 12 nm in diameter (3 nm-, 6 nm-, and 12 nm-FePt) were synthesized and applied as a dual modality contrast agent for CT/MRI molecular imaging. These nanoparticles present excellent biocompatibility and hemocompatibility in all test concentrations for the imaging contrast. The biodistribution analysis revealed the highest serum concentration and circulation half-life for 12 nm-FePt, followed by 6 nm-FePt then 3 nm-FePt. Thus, the 3 nm-FePt showed higher brain concentrations. Anti-Her2 antibody conjugated FePt nanoparticles demonstrated molecular expression dependent CT/MRI dual imaging contrast effect in MBT2 cell line and its Her2/neu gene knock out counterpart. Selective contrast enhancement of Her2/neu overexpression cancer lesions in both CT and MRI was found in tumor bearing animal after tail vein injection of the nanoparticles. The 12 nm-FePt outperformed 3 nm-FePt in both imaging modalities. These results indicate the potential of FePt nanoparticles to serve as novel multimodal molecular imaging contrast agents in clinical settings.